Search

Your search keyword '"Spriano, Mauro"' showing total 45 results
Start Over Author "Spriano, Mauro"
45 results on '"Spriano, Mauro"'

1. Data from Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion

Author

Mosca, Laura, primary, Fabris, Sonia, primary, Lionetti, Marta, primary, Todoerti, Katia, primary, Agnelli, Luca, primary, Morabito, Fortunato, primary, Cutrona, Giovanna, primary, Andronache, Adrian, primary, Matis, Serena, primary, Ferrari, Francesco, primary, Gentile, Massimo, primary, Spriano, Mauro, primary, Callea, Vincenzo, primary, Festini, Gianluca, primary, Molica, Stefano, primary, Deliliers, Giorgio Lambertenghi, primary, Bicciato, Silvio, primary, Ferrarini, Manlio, primary, and Neri, Antonino, primary

Published
2023
Full Text
View/download PDF

2. Supplementary Data from Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion

Author

Mosca, Laura, primary, Fabris, Sonia, primary, Lionetti, Marta, primary, Todoerti, Katia, primary, Agnelli, Luca, primary, Morabito, Fortunato, primary, Cutrona, Giovanna, primary, Andronache, Adrian, primary, Matis, Serena, primary, Ferrari, Francesco, primary, Gentile, Massimo, primary, Spriano, Mauro, primary, Callea, Vincenzo, primary, Festini, Gianluca, primary, Molica, Stefano, primary, Deliliers, Giorgio Lambertenghi, primary, Bicciato, Silvio, primary, Ferrarini, Manlio, primary, and Neri, Antonino, primary

Published
2023
Full Text
View/download PDF

3. The addition of radiotherapy to chemotherapy does not improve outcome of early stage Hodgkin’s lymphoma patients: a retrospective long-term follow-up analysis of a regional Italian experience

Author

Olcese, Francesca, Clavio, Marino, Rossi, Edoardo, Spriano, Mauro, Ballerini, Filippo, Canepa, Letizia, Pierri, Ivana, Aquino, Sara, Varaldo, Riccardo, Manna, Annunziata, Secondo, Vincenzo, Racchi, Omar, Balleari, Enrico, Orcioni, Giulio Fraternali, Carella, Angelo Michele, Ghio, Riccardo, and Gobbi, Marco

Published
2009
Full Text
View/download PDF

5. Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study

Author

Gentile, Massimo, Cutrona, Giovanna, Fabris, Sonia, Pesce, Emanuela Anna, Baldini, Luca, Di Raimondo, Francesco, Musolino, Caterina, Di Tonno, Paolo, Di Renzo, Nicola, Molica, Stefano, Brugiatelli, Maura, Ilariucci, Fiorella, Zupo, Simona, Matis, Serena, Maura, Francesco, Vigna, Ernesto, Angrilli, Francesco, Recchia, Anna Grazia, Quarta, Giovanni, Iannitto, Emilio, Fragasso, Alberto, Musto, Pellegrino, Spriano, Mauro, Vincelli, Iolanda, Vallisa, Daniele, Cortelezzi, Agostino, Mauro, Francesca Romana, Foà, Robin, Federico, Massimo, Neri, Antonino, Ferrarini, Manlio, and Morabito, Fortunato

Published
2013
Full Text
View/download PDF

6. Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide

Author

Musto, Pellegrino, Falcone, Antonietta, Sanpaolo, Grazia, Guglielmelli, Tommasina, Zambello, Renato, Balleari, Enrico, Catalano, Lucio, Spriano, Mauro, Cavallo, Federica, Sala, Antonio La, Mantuano, Saverio, Nobile, Michele, Melillo, Lorella, Scalzulli, Potito Rosario, Dell’Olio, Matteo, Bodenizza, Carlo, Greco, Michele Mario, Carella, Angelo Michele, Jr., Merla, Emanuela, Carella, Angelo Michele, Boccadoro, Mario, Cascavilla, Nicola, and Palumbo, Antonio

Published
2006
Full Text
View/download PDF

8. Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia

Author

Morabito, Fortunato, Cutrona, Giovanna, Gentile, Massimo, Matis, Serena, Todoerti, Katia, Colombo, Monica, Sonaglio, Claudia, Fabris, Sonia, Reverberi, Daniele, Megna, Mauro, Spriano, Mauro, Lucia, Eugenio, Rossi, Edoardo, Callea, Vincenzo, Mazzone, Carla, Festini, Gianluca, Zupo, Simonetta, Molica, Stefano, Neri, Antonino, and Ferrarini, Manlio

Published
2009
Full Text
View/download PDF

10. Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I–II GIMEMA trial

Author

Mauro, Francesca R., primary, Carella, Angelo M., additional, Molica, Stefano, additional, Paoloni, Francesca, additional, Liberati, Anna M., additional, Zaja, Francesco, additional, Belsito, Valeria, additional, Cortellezzi, Agostino, additional, Rizzi, Rita, additional, Tosi, Patrizia, additional, Spriano, Mauro, additional, Ferretti, Antonietta, additional, Nanni, Mauro, additional, Marinelli, Marilisa, additional, De Propris, Maria S., additional, Orlando, Sonia M., additional, Vignetti, Marco, additional, Cuneo, Antonio, additional, Guarini, Anna R., additional, and Foà, Robin, additional

Published
2016
Full Text
View/download PDF

11. Double Autologous Stem Cell Transplantation Significantly Prolongs Progression-Free Survival and Overall Survival in Comparison with Single Autotransplantation in Newly Diagnosed Multiple Myeloma: An Analysis of Phase 3 EMN02/HO95 Study

Author

Cavo, Michele, Gay, Francesca Maria, Patriarca, Francesca, Zamagni, Elena, Montefusco, Vittorio, Dozza, Luca, Galli, Monica, Bringhen, Sara, Testoni, Nicoletta, Grasso, Mariella, Ballanti, Stelvio, Tacchetti, Paola, Semenzato, Giampietro, Liberati, Anna Marina, Benevolo, Giulia, Spriano, Mauro, Di Bartolomeo, Paolo, Caravita di Toritto, Tommaso, Palmas, Angelo D., Cafro, Anna Maria, Morabito, Fortunato, Musto, Pellegrino, Rizzi, Rita, Palumbo, Antonio, and Sonneveld, Pieter

Published
2017
Full Text
View/download PDF

12. Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I–II GIMEMA trial.

Author

Mauro, Francesca R., Carella, Angelo M., Molica, Stefano, Paoloni, Francesca, Liberati, Anna M., Zaja, Francesco, Belsito, Valeria, Cortellezzi, Agostino, Rizzi, Rita, Tosi, Patrizia, Spriano, Mauro, Ferretti, Antonietta, Nanni, Mauro, Marinelli, Marilisa, De Propris, Maria S., Orlando, Sonia M., Vignetti, Marco, Cuneo, Antonio, Guarini, Anna R., and Foà, Robin

Subjects
CHRONIC lymphocytic leukemia, REFRACTORY anemia, FLUDARABINE, CYCLOPHOSPHAMIDE, CHRONIC lymphocytic leukemia treatment
Abstract

The activity and safety of a regimen combining lenalidomide with fludarabine and cyclophosphamide (FC) was investigated in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Treatment consisted of six monthly courses of the FC regimen combined with 14 days of lenalidomide given at the starting dose of 2.5 mg during course 1. The maximum tolerated dose of lenalidomide was 5 mg. Forty patients were assessed for response, 66% wereIGHVunmutated, 45% showed deletion 11q or 17p. The overall response and complete remission rates were 62.5% and 22.5%, respectively, the median progression-free and overall survival (OS) were 19 and 45 months, respectively. Grade 3–4 granulocytopenia was observed in 65% of cases, severe infections in 7.5%, the lenalidomide-related toxicity was mild. In conclusion, the results of this study demonstrate that low-dose lenalidomide associated with the FC schedule is an effective treatment for R/R patients with CLL, associated with an acceptable safety profile. [ABSTRACT FROM PUBLISHER]

Published
2017
Full Text
View/download PDF

13. Inclusion of Total BODY Computed Tomography (TB-CT) SCANS In the INITIAL WORK-up of Binet STAGE A CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS On CLINICAL Grounds: PRELIMINARY RESULTS of the Prospective, MULTICENTER O-CLL1- GISL STUDY

Author

Gentile, Massimo, primary, Cutrona, Giovanna, additional, Fabris, Sonia, additional, Pesce, Emanuela Anna, additional, Maura, Francesco, additional, Raimondo, Francesco Di, additional, Musolino, Caterina, additional, Di Tonno, Paolo, additional, Di Renzo, Nicola, additional, Levato, Luciano, additional, Brugiatelli, Maura, additional, Merli, Francesco, additional, Zupo, Simonetta, additional, Matis, Serena, additional, Ilariucci, Fiorella, additional, Angrilli, Francesco, additional, Quarta, Giovanni, additional, Iannitto, Emilio, additional, Fragasso, Alberto, additional, Molica, Stefano, additional, Musto, Pellegrino, additional, Spriano, Mauro, additional, Vincelli, Iolanda, additional, Vallisa, Daniele, additional, Cortelezzi, Agostino, additional, Foà, Robin, additional, Federico, Massimo, additional, Neri, Antonino, additional, Ferrarini, Manlio, additional, and Morabito, Fortunato, additional

Published
2011
Full Text
View/download PDF

14. An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia

Author

Montillo, Marco, primary, Tedeschi, Alessandra, additional, Petrizzi, Valeria Belsito, additional, Ricci, Francesca, additional, Crugnola, Monica, additional, Spriano, Mauro, additional, Spedini, Pierangelo, additional, Ilariucci, Fiorella, additional, Uziel, Lilj, additional, Attolico, Immacolata, additional, Vismara, Eleonora, additional, De Blasio, Angelo, additional, Zaccaria, Alfonso, additional, and Morra, Enrica, additional

Published
2011
Full Text
View/download PDF

15. Therapy of Hodgkin’s lymphoma in clinical practice: A retrospective long-term follow-up analysis

Author

AQUINO, SARA, primary, CLAVIO, MARINO, additional, ROSSI, EDOARDO, additional, VIGNOLO, LUANA, additional, MIGLINO, MAURIZIO, additional, SPRIANO, MAURO, additional, CANEPA, LETIZIA, additional, CATANIA, GIOACCHINO, additional, PIERRI, IVANA, additional, BERGAMASCHI, MICAELA, additional, GONELLA, ROBERTA, additional, MARANI, CARLO, additional, RACCHI, OMAR, additional, CAVALIERE, MARINA, additional, GORETTI, RICCARDO, additional, CARBONE, FEDERICO, additional, BRUZZONE, ANDREA, additional, TASSARA, RODOLFO, additional, CARELLA, ANGELO MICHELE, additional, GHIO, RICCARDO, additional, and GOBBI, MARCO, additional

Published
2011
Full Text
View/download PDF

16. Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion

Author

Mosca, Laura, primary, Fabris, Sonia, additional, Lionetti, Marta, additional, Todoerti, Katia, additional, Agnelli, Luca, additional, Morabito, Fortunato, additional, Cutrona, Giovanna, additional, Andronache, Adrian, additional, Matis, Serena, additional, Ferrari, Francesco, additional, Gentile, Massimo, additional, Spriano, Mauro, additional, Callea, Vincenzo, additional, Festini, Gianluca, additional, Molica, Stefano, additional, Deliliers, Giorgio Lambertenghi, additional, Bicciato, Silvio, additional, Ferrarini, Manlio, additional, and Neri, Antonino, additional

Published
2010
Full Text
View/download PDF

17. Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC) In Relapsed/Refractory Patients with B-Cell Chronic Lymphocytic Leukemia (CLL): Final Report of the Italian Study

Author

Montillo, Marco, primary, Tedeschi, Alessandra, additional, Ricci, Francesca, additional, Zaccaria, Alfonso, additional, Crugnola, Monica, additional, Spriano, Mauro, additional, Spedini, PierAngelo, additional, Ilariucci, Fiorella, additional, Uziel, Lilj, additional, Attolico, Immacolata, additional, De Blasio, Angelo, additional, Vismara, Eleonora, additional, Morra, Enrica, additional, and Petrizzi, Valeria Belsito, additional

Published
2010
Full Text
View/download PDF

18. Prognostic relevance ofin vitroresponse to cell stimulation via surface IgD in binet stage a CLL

Author

Morabito, Fortunato, primary, Cutrona, Giovanna, additional, Gentile, Massimo, additional, Fabbi, Marina, additional, Matis, Serena, additional, Colombo, Monica, additional, Reverberi, Daniele, additional, Megna, Mauro, additional, Spriano, Mauro, additional, Callea, Vincenzo, additional, Vigna, Ernesto, additional, Rossi, Edoardo, additional, Lucia, Eugenio, additional, Festini, Gianluca, additional, Zupo, Simonetta, additional, Molica, Stefano, additional, Neri, Antonino, additional, and Ferrarini, Manlio, additional

Published
2010
Full Text
View/download PDF

19. Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma

Author

Corso, Alessandro, primary, Barbarano, Luciana, additional, Mangiacavalli, Silvia, additional, Spriano, Mauro, additional, Alessandrino, Emilio P., additional, Cafro, Anna Maria, additional, Pascutto, Cristiana, additional, Varettoni, Marzia, additional, Bernasconi, Paolo, additional, Grillo, Giovanni, additional, Carella, Angelo M., additional, Montalbetti, Luigi, additional, Lazzarino, Mario, additional, and Morra, Enrica, additional

Published
2009
Full Text
View/download PDF

20. Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients.

Author

Sacchi, Stefano, primary, Marcheselli, Luigi, primary, Pozzi, Samantha, primary, Bari, Alessia, primary, Luminari, Stefano, primary, Ilariucci, Fiorella, primary, Stelitano, Caterina, primary, Angrilli, Francesco, primary, Lazzaro, Antonio, primary, Baldini, Luca, primary, Spriano, Mauro, primary, Caparrotti, Giuseppe, primary, Musso, Maurizio, primary, Quarta, Giovanni, primary, and Brugiatelli, Maura, primary

Published
2008
Full Text
View/download PDF

21. Biological and Clinical Relevance of Surrogate Markers of IgVH Mutational Status in B-Cell Chronic Lymphocytic Leukemia.

Author

Morabito, Fortunato, primary, Lionetti, Marta, primary, Cutrona, Giovanna, primary, Todoerti, Katia, primary, Matis, Serena, primary, Gentile, Massimo, primary, Spriano, Mauro, primary, Callea, Vincenzo, primary, Festini, Gianluca, primary, Molica, Stefano, primary, Deliliers, Giorgio Lambertenghi, primary, Ferrarini, Manlio, primary, and Neri, Antonino, primary

Published
2008
Full Text
View/download PDF

22. Genome-Wide DNA Copy Number Analysis by SNP Arrays of B-Cell Chronic Lymphocytic Leukemia: Correlation with Known Biological and Molecular Prognostic Markers.

Author

Mosca, Laura, primary, Fabris, Sonia, primary, Cutrona, Giovanna, primary, Agnelli, Luca, primary, Matis, Serena, primary, Gentile, Massimo, primary, Spriano, Mauro, primary, Callea, Vincenzo, primary, Festini, Gianluca, primary, Molica, Stefano, primary, Mammi, Caterina, primary, Federico, Massimo, primary, Deliliers, Giorgio Lambertenghi, primary, Morabito, Fortunato, primary, Ferrarini, Manlio, primary, and Neri, Antonino, primary

Published
2008
Full Text
View/download PDF

23. Equivalent Efficacy and Lower Toxicity of Subcutaneous Cladribine at Reduced Doses (Five versus Seven Consecutive days) in Hairy Cell Leukemia: An Interim Analysis of the ICGHCL 2004 Protocol by the Italian Cooperative Group on Hcl

Author

Forconi, Francesco, primary, Zaja, Francesco, primary, Intermesoli, Tamara, primary, Rigacci, Luigi, primary, Stelitano, Caterina, primary, Tavera, Silvia, primary, Morello, Enrico, primary, Pulsoni, Alessandro, primary, Gherlinzoni, Filippo, primary, Zaccaria, Alfonso, primary, Baraldi, Anna, primary, Pierri, Ivana, primary, Cantaffa, Renato, primary, Martinelli, Giovanni, primary, Barulli, Sara, primary, Morabito, Fortunato, primary, Zinzani, Pier Luigi, primary, Spriano, Mauro, primary, Galieni, Piero, primary, Caremani, Alessandra, primary, Pietrini, Alice, primary, Cencini, Emanuele, primary, Tassi, Maristella, primary, Raspadori, Donatella, primary, and Lauria, Francesco, primary

Published
2008
Full Text
View/download PDF

24. Molecular and transcriptional characterization of 17p loss in B‐cell chronic lymphocytic leukemia

Author

Fabris, Sonia, primary, Mosca, Laura, additional, Todoerti, Katia, additional, Cutrona, Giovanna, additional, Lionetti, Marta, additional, Intini, Daniela, additional, Matis, Serena, additional, Colombo, Monica, additional, Agnelli, Luca, additional, Gentile, Massimo, additional, Spriano, Mauro, additional, Callea, Vincenzo, additional, Festini, Gianluca, additional, Molica, Stefano, additional, Lambertenghi Deliliers, Giorgio, additional, Morabito, Fortunato, additional, Ferrarini, Manlio, additional, and Neri, Antonino, additional

Published
2008
Full Text
View/download PDF

26. Bortezomib with HIG-Dose Dexamethasone as First Line Therapy in Patients with Multiple Myeloma Candidates to High-Dose Therapy.

Author

Corso, Alessandro, primary, Barbarano, Luciana, primary, Mangiacavalli, Silvia, primary, Montalbetti, Luigi, primary, Brasca, Paola, primary, Zappasodi, Patrizia, primary, Carella, Angelo, primary, Spriano, Mauro, primary, Alessandrino, Emilio Paolo, primary, Cairoli, Roberto, primary, Petrò, Daniela, primary, Varettoni, Marzia, primary, Bernasconi, Paolo, primary, Lazzarino, Mario, primary, and Morra, Enrica, primary

Published
2007
Full Text
View/download PDF

27. Combined Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC), an Active Regimen for Treated Patients with Chronic Lymphocytic Leukemia (CLL).

Author

Montillo, Marco, primary, Miqueleiz, Sara, additional, Tedeschi, Alessandra, additional, Ricci, Francesca, additional, Vismara, Eleonora, additional, Ciapanna, Denis, additional, Petrizzi, Valeria Belsito, additional, Crugnola, Monica, additional, Spriano, Mauro, additional, Uziel, Lilj, additional, De Blasio, Angelo, additional, Spedini, Pierangelo, additional, and Morra, Enrica, additional

Published
2007
Full Text
View/download PDF

28. Laparoscopic Lymph Node Biopsy in Intra-abdominal Lymphoma

Author

Casaccia, Marco, primary, Torelli, Paolo, additional, Cavaliere, Davide, additional, Panaro, Fabrizio, additional, Nardi, Ilaria, additional, Rossi, Edoardo, additional, Spriano, Mauro, additional, Bacigalupo, Andrea, additional, Gentile, Raffaella, additional, and Valente, Umberto, additional

Published
2007
Full Text
View/download PDF

29. Definition of a Prognostic Scoring System for Predicting Clinical Outcome in B-Cell Chronic Lymphocytic Leukemia.

Author

Morabito, Fortunato, primary, Cutrona, Giovanna, additional, Gentile, Massimo, additional, Matis, Serena, additional, Colombo, Monica, additional, Lucia, Eugenio, additional, Spriano, Mauro, additional, Rossi, Edoardo, additional, Callea, Vincenzo, additional, Stelitano, Caterina, additional, Mazzone, Carla, additional, Vigna, Ernesto, additional, Gentile, Carlo, additional, Festini, Gianluca, additional, Neri, Antonino, additional, Zupo, Simonetta, additional, Molica, Stefano, additional, Chiorazzi, Nicholas, additional, and Ferrarini, Manlio, additional

Published
2006
Full Text
View/download PDF

30. Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw.

Author

Pozzi, Samantha, primary, Marcheselli, Raffaella, primary, Sacchi, Stefano, primary, Quarta, Giovanni, primary, Musto, Pellegrino, primary, Caparrotti, Giuseppe, primary, Natale, Donato, primary, Pianezze, Graziano, primary, Polimeno, Giuseppe, primary, Pitini, Vincenzo, primary, Ponchio, Luisa, primary, Broglia, Chiara, primary, Spriano, Mauro, primary, Musso, Maurizio, primary, Masini, Luciano, primary, Donelli, Amedea, primary, Dini, Daniele, primary, Leonardi, Giovanna, primary, Luminari, Stefano, primary, and Pollastri, Giuseppe, primary

Published
2005
Full Text
View/download PDF

31. Fludarabine, Cyclophosphamide and Mitoxantrone for Untreated Follicular Lymphoma: a Report from the Non-Hodgkin's Lymphoma Co-operative Study Group

Author

Santini, Gino, primary, Chisesi, Teodoro, additional, Nati, Sandro, additional, Porcellini, Adolfo, additional, Zoli, Valerio, additional, Rizzoli, Vittorio, additional, Zupo, Simona, additional, Marino, Gennaro, additional, Rubagotti, Alessandra, additional, Polacco, Alessandro, additional, Spriano, Mauro, additional, Vimercati, Renato, additional, Congiu, Angela Marina, additional, Ravetti, Jean Louis, additional, Aversa, Savina, additional, Candela, Marco, additional, and Patti, Caterina, additional

Published
2004
Full Text
View/download PDF

32. High-Dose Cyclophosphamide Followed by Autografting Can Improve the Outcome of Relapsed or Resistant Non-Hodgkin's Lymphomas with Involved or Hypoplastic Bone Marrow

Author

Santini, Gino, primary, Souza, Carmino De, additional, Congiu, Angela Marina, additional, Nati, Sandro, additional, Marino, Gennaro, additional, Soracco, Monica, additional, Sertoli, Mario Roberto, additional, Rubagotti, Alessandra, additional, Spriano, Mauro, additional, Vassallo, Franca, additional, Rossi, Edoardo, additional, Vimercati, Renato, additional, Piaggio, Giovanna, additional, Figari, Osvaldo, additional, Benvenuto, Federica, additional, Abate, Monica, additional, Truini, Mauro, additional, Ravetti, Jean Louis, additional, Ribizzi, Iole, additional, and Damasio, Eugenio, additional

Published
1999
Full Text
View/download PDF

33. Twelve Years Experience with High-Dose Therapy and Autologous Stem Cell Transplantation for High-Risk Hodgkin's Disease Patients in First Remission After MOPP/ABVD Chemotherapy

Author

Carella, Angelo Michele, primary, Prencipe, Emma, additional, Pungolino, Ester, additional, Lerma, Enrica, additional, Frassoni, Francesco, additional, Rossi, Edoardo, additional, Giordano, Domenico, additional, Occhini, Domenico, additional, Gatti, Anna M., additional, Bruni, Roberta, additional, Spriano, Mauro, additional, Nati, Sandro, additional, Pierluigi, Daniela, additional, Congiu, Marina, additional, Vimercati, Renato, additional, Ravetti, Jean Louis, additional, and Federico, Massimo, additional

Published
1996
Full Text
View/download PDF

34. Impact of Interferon at Induction Chemotherapy and Maintenance Treatment for Multiple Myeloma Preliminary results of a multicenter study by the Italian Non-Hodgkin's Lymphoma Cooperative Study Group (NHLCSG)

Author

Capnist, Giovanni, primary, Vespignani, Michele, additional, Spriano, Mauro, additional, Damasio, Eugenio, additional, Craviotto, Luisa, additional, Rizzoli, Vittorio, additional, Contu, Antonio, additional, Olmeo, Nina, additional, Tedeschi, Lucilla, additional, Fabris, Piero, additional, and Chisesi, Teodoro, additional

Published
1994
Full Text
View/download PDF

35. Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma.

Author

Corso, Alessandro, Barbarano, Luciana, Mangiacavalli, Silvia, Spriano, Mauro, Alessandrino, Emilio P., Cafro, Anna Maria, Pascutto, Cristiana, Varettoni, Marzia, Bernasconi, Paolo, Grillo, Giovanni, Carella, Angelo M., Montalbetti, Luigi, Lazzarino, Mario, and Morra, Enrica

Subjects
DEXAMETHASONE, PREGNANE, MULTIPLE myeloma, B cell lymphoma, MONOCLONAL gammopathies, ETOPOSIDE, ANTINEOPLASTIC agents
Abstract

The aim of this phase II trial was to investigate the efficacy of bortezomib plus dexamethasone (Vel-Dex) as induction therapy in patients with multiple myeloma (MM) and to define the role of intensification before transplantation. Fifty-seven patients were treated with four courses of Vel-Dex, two cycles of dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP), and a single autologous transplant. Fourteen patients (25%) went off-study: seven after Vel-Dex, seven after DCEP. All patients yielded high numbers of stem cells (median CD34+ cells 7.5 × 106/kg); 54 of the 57 patients (94%) collected ≥4 × 106/kg CD34+ cells, 60% with a single leukapheresis. The overall response rate (ORR) after Vel-Dex was 86% (70% had a very good partial response [VGPR] or better) regardless of cytogenetic abnormalities and International Staging System stage (ISS). The response at the end of the two DCEP cycles remained unchanged in 35 patients (70%), worsened in 15 (20%), and improved in 5 (10%). Because of the consistent drop-out, the ORR in intention-to-treat analysis decreased significantly from 86% after Vel-Dex to 76% after DCEP, and 73% after transplantation. However, when considering the subset of 43 patients who completed the program, the ORR was 96% (complete response 39%, VGPR 41%, partial response 16%). In conclusion, Vel-Dex produces high response rates, improves stem cell collection, and overcomes the need for intensification before autologous transplantation. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

36. Autologous Unpurged Bone Marrow Transplantation for Acute Non Lymphoblastic Leukemia in First Remission

Author

Carella, Angelo M., primary, Nati, Sandro, additional, Carlier, Paolo, additional, Pierluigi, Daniela, additional, Giordano, Domenico, additional, Congiu, Angela, additional, Santini, Gino, additional, Scarpati, Daniele, additional, Barra, Salvina, additional, Corvo, Renzo, additional, Vitale, Vito, additional, Raffo, Maria R., additional, Cerri, Raffaella, additional, Risso, Marco, additional, Spriano, Mauro, additional, Vimercati, Renato, additional, Pungolino, Ester, additional, Bacigalupo, Andrea, additional, and Damasio, Eugenio, additional

Published
1991
Full Text
View/download PDF

37. A New Combination of Idarubicin, Etoposide and Cytarabine in Untreated Acute Non-Lymphoblastic Leukemia

Author

Carella, Angelo M., primary, Gaozza, Eugenia, additional, Piatti, Gabriell, additional, Nati, Sandro, additional, Pungoltno, Ester, additional, Santini, Gino, additional, Giordano, Domenico, additional, Cerri, Raffaella, additional, Risso, Marco, additional, Rossi, Edoardo, additional, Spriano, Mauro, additional, Coingiu, Angela, additional, Carlier, Paolo, additional, Raffo, Maria R., additional, Damagio, Eugenio, additional, Bacigalupo, Andrea, additional, and Marmont, Alberto M., additional

Published
1990
Full Text
View/download PDF

39. Recombinant Human Erythropoietin in the Anemia Associated With Multiple Myeloma or Non-Hodgkin’s Lymphoma: Dose Finding and Identification of Predictors of Response

Author

Cazzola, Mario, Messinger, Diethelm, Battistel, Vittorio, Bron, Dominique, Cimino, Renato, Enller-Ziegler, Liana, Essers, Ute, Greil, Richard, Grossi, Alberto, Jäger, Gerard, LeMevel, Annick, Najman, Albert, Silingardi, Vittorio, Spriano, Mauro, Hoof, Achiel van, and Ehmer, Bernhard

Abstract

Previous phase I-II clinical trials have shown that recombinant human erythropoietin (rHuEpo) can ameliorate anemia in a portion of patients with multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL). Therefore, we performed a randomized controlled multicenter study to define the optimal initial dosage and to identify predictors of response to rHuEpo. A total of 146 patients who had hemoglobin (Hb) levels ≤11 g/dL and who had no need for transfusion at the time of enrollment entered this trial. Patients were randomized to receive 1,000 U (n = 31), 2,000 U (n = 29), 5,000 U (n = 31), or 10,000 U (n = 26) of rHuEpo daily subcutaneously for 8 weeks or to receive no therapy (n = 29). Of the patients, 84 suffered from MM and 62 from low- to intermediate-grade NHL, including chronic lymphocytic leukemia; 116 of 146 (79%) received chemotherapy during the study. The mean baseline Hb level was 9.4 ± 1.0 g/dL. The median serum Epo level was 32 mU/mL, and endogenous Epo production was found to be defective in 77% of the patients, as judged by a value for the ratio of observed-to-predicted serum Epo levels (O/P ratio) of ≤0.9. An intention-to-treat analysis was performed to evaluate treatment efficacy. The median average increase in Hb levels per week was 0.04 g/dL in the control group and –0.04 (P= .57), 0.22 (P= .05), 0.43 (P= .01), and 0.58 (P= .0001) g/dL in the 1,000 U, 2,000 U, 5,000 U, and 10,000 U groups, respectively (Pvalues versus control). The probability of response (ΔHb ≥ 2 g/dL) increased steadily and, after 8 weeks, reached 31% (2,000 U), 61% (5,000 U), and 62% (10,000 U), respectively. Regression analysis using Cox’s proportional hazard model and classification and regression tree analysis showed that serum Epo levels and the O/P ratio were the most important factors predicting response in patients receiving 5,000 or 10,000 U. Approximately three quarters of patients presenting with Epo levels inappropriately low for the degree of anemia responded to rHuEpo, whereas only one quarter of those with adequate Epo levels did so. Classification and regression tree analysis also showed that doses of 2,000 U daily were effective in patients with an average platelet count greater than 150 × 109/L. About 50% of these patients are expected to respond to rHuEpo. Thus, rHuEpo was safe and effective in ameliorating the anemia of MM and NHL patients who showed defective endogenous Epo production. From a practical point of view, we conclude that the decision to use rHuEpo in an individual anemic patient with MM or NHL should be based on serum Epo levels, whereas the choice of the initial dosage should be based on residual marrow function.

Published
1995
Full Text
View/download PDF

40. Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I–II GIMEMA trial

Author

Robin Foà, Patrizia Tosi, Francesco Zaja, Marco Vignetti, Francesca Romana Mauro, Antonietta Ferretti, Marilisa Marinelli, Rita Rizzi, Agostino Cortellezzi, Mauro Nanni, Antonio Cuneo, Mauro Spriano, Sonia Maria Orlando, Maria Stefania De Propris, Anna M. Liberati, Anna Guarini, Angelo Michele Carella, Stefano Molica, Valeria Belsito, Francesca Paoloni, Mauro, Francesca R, Carella, Angelo M., Molica, Stefano, Paoloni, Francesca, Liberati, Anna M., Zaja, Francesco, Belsito, Valeria, Cortellezzi, Agostino, Rizzi, Rita, Tosi, Patrizia, Spriano, Mauro, Ferretti, Antonietta, Nanni, Mauro, Marinelli, Marilisa, De Propris, Maria S., Orlando, Sonia M., Vignetti, Marco, Cuneo, Antonio, Guarini, Anna R., and Foà, Robin

Subjects
Male, Cancer Research, Chronic lymphocytic leukemia, Gastroenterology, 0302 clinical medicine, Recurrence, Cause of Death, Antineoplastic Combined Chemotherapy Protocols, Medicine, Remission Induction, Hematology, Middle Aged, Thalidomide, Fludarabine, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Female, IGHV@, Vidarabine, medicine.drug, Adult, medicine.medical_specialty, Maximum Tolerated Dose, Cyclophosphamide, lenalidomide, Drug Administration Schedule, NO, 03 medical and health sciences, Refractory, Internal medicine, Humans, cyclophosphamide, fludarabine, refractory, relapsed, FC Regimen, Aged, Lenalidomide, business.industry, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, Survival Analysis, Regimen, Drug Resistance, Neoplasm, Immunology, business, 030215 immunology
Abstract

The activity and safety of a regimen combining lenalidomide with fludarabine and cyclophosphamide (FC) was investigated in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Treatment consisted of six monthly courses of the FC regimen combined with 14 days of lenalidomide given at the starting dose of 2.5 mg during course 1. The maximum tolerated dose of lenalidomide was 5 mg. Forty patients were assessed for response, 66% were IGHV unmutated, 45% showed deletion 11q or 17p. The overall response and complete remission rates were 62.5% and 22.5%, respectively, the median progression-free and overall survival (OS) were 19 and 45 months, respectively. Grade 3–4 granulocytopenia was observed in 65% of cases, severe infections in 7.5%, the lenalidomide-related toxicity was mild. In conclusion, the results of this study demonstrate that low-dose lenalidomide associated with the FC schedule is an effective treatment for R/R patients with CLL, associated with an acceptable safety profile. © 2016 Informa UK Limited, trading as Taylor & Francis Group

Published
2017

41. Seventeen years of experience with ATRA-based therapy for acute promyelocytic leukaemia: long-term follow-up of patients treated at S. Martino Hospital, Genoa.

Author

Clavio M, Ghiso A, Ghiggi C, Spriano M, Colombo N, Grasso R, Varaldo R, Miglino M, Pierri I, Olcese F, Aquino S, Biasco S, Balleari E, Carella AM, Sessarego M, and Gobbi M

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Leukemia, Promyelocytic, Acute mortality, Male, Middle Aged, Recurrence, Retrospective Studies, Antineoplastic Agents administration & dosage, Leukemia, Promyelocytic, Acute drug therapy, Tretinoin administration & dosage
Abstract

We conducted a long-term follow-up retrospective study on 91 consecutive newly diagnosed acute promyelocytic leukaemia (APL) patients. Induction and consolidation therapy were well-tolerated by most patients. Of the 79 patients who were initially treated with the all-trans retinoic acid (ATRA)-containing regimens, there were 3 haemorrhagic deaths during the first period of therapy (4%) and one in consolidation which was due to infection. Following consolidation, molecular assessment of response was performed on 67 patients, and 66 were found to have achieved cytogenetic and molecular remission (98%). After a median follow-up of 100 months (12-192), 10 of the 75 patients who achieved complete remission (13%) relapsed. Seventy-eight percent of the patients were expected to be alive at 14 years from diagnosis, i.e., 90 and 48% of patients of intermediate-low risk and high risk at presentation, respectively (p=0.0009). Sixty-nine patients were in molecular remission after first-line and/or salvage therapy (74%). To date, 4 patients out of the 91 have undergone salvage allogeneic transplant (4%).

Published
2009
Full Text
View/download PDF

42. Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells.

Author

Cutrona G, Colombo M, Matis S, Fabbi M, Spriano M, Callea V, Vigna E, Gentile M, Zupo S, Chiorazzi N, Morabito F, and Ferrarini M

Subjects
Apoptosis immunology, Biomarkers, Clone Cells chemistry, Clone Cells immunology, Cohort Studies, Humans, Immunologic Capping, Neoplastic Stem Cells chemistry, Phosphorylation, Protein Processing, Post-Translational, Protein-Tyrosine Kinases metabolism, Signal Transduction immunology, Tumor Cells, Cultured cytology, Tumor Cells, Cultured immunology, ADP-ribosyl Cyclase 1 analysis, Immunoglobulin M immunology, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Neoplastic Stem Cells immunology, Receptors, Antigen, B-Cell immunology, ZAP-70 Protein-Tyrosine Kinase analysis
Abstract

Background: Patients with chronic lymphocytic leukemia whose cells express CD38 and ZAP-70 and utilize unmutated Ig VH region genes have a very poor prognosis. We studied whether cells expressing CD38 and ZAP-70 are more susceptible to stimulation through B-cell receptors than are cells that do not express CD38 and ZAP-70., Design and Methods: CD38-positive and CD38-negative leukemic cells were separated from single cases and compared for their response to B-cell receptor cross-linking and ZAP-70 expression. Cohort studies were also carried out by measuring the apoptotic response to surface immunoglobulin M (IgM) cross-linking in 82 patients with chronic lymphocytic leukemia and the protein tyrosine phosphorylation induced by surface IgM in 21 patients., Results: CD38-positive cells, isolated from cases of chronic lymphocytic leukemia classified as CD38-positive or CD38-negative, expressed more ZAP-70 than the corresponding CD38-negative cells, exhibited more robust protein tyrosine phosphorylation and had a greater tendency to apoptosis upon B-cell receptor cross-linking. In the cohort studies, surface IgM-induced protein tyrosine phosphorylation correlated significantly with CD38 and ZAP-70 expression and with the absence of Ig VH gene mutations. Apoptosis induced by surface IgM cross-linking correlated significantly only with the proportion of CD38-positive cells. Difficulties in finding more definitive correlations were probably related to imprecision in the in vitro test system and in the definition of cases as positive or negative., Conclusions: Collectively, these data indicate that CD38-positive, ZAP-70-positive cells have a greater capacity for signaling through the B-cell receptor and suggest a function for B-cell receptor signaling in promoting chronic lymphocytic leukemia cell expansion, especially within the CD38-positive fraction of the leukemic clone.

Published
2008
Full Text
View/download PDF

43. Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients.

Author

Pozzi S, Marcheselli R, Sacchi S, Baldini L, Angrilli F, Pennese E, Quarta G, Stelitano C, Caparotti G, Luminari S, Musto P, Natale D, Broglia C, Cuoghi A, Dini D, Di Tonno P, Leonardi G, Pianezze G, Pitini V, Polimeno G, Ponchio L, Masini L, Musso M, Spriano M, and Pollastri G

Subjects
Adult, Aged, Aged, 80 and over, Diphosphonates therapeutic use, Female, Humans, Incidence, Jaw Diseases epidemiology, Male, Middle Aged, Models, Biological, Osteonecrosis epidemiology, Retrospective Studies, Diphosphonates adverse effects, Jaw Diseases chemically induced, Multiple Myeloma drug therapy, Osteonecrosis chemically induced
Abstract

Over a period of 28 months, we observed five cases of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates (BP) at our institution. This prompted us to undertake a retrospective, multicenter study to analyse the characteristics of patients who exhibited ONJ and to define the frequency of ONJ in multiple myeloma (MM). We identified 35 cases in Gruppo Italiano Studio Linfomi centers during the period 2002 - 05. The median time from cancer diagnosis to the clinical onset of ONJ was 70 months. In these 35 cases of ONJ, 24 appeared 20 - 60 months after starting BP treatment. The time for the onset of ONJ was significantly shorter for patients treated with zoledronic acid alone than for those treated with pamidronate followed by zoledronic acid. The frequency of ONJ in the MM group during the study period was 1.9%, although the nature of the present study may have resulted in an underestimation of ONJ cases. Our analysis strongly suggested an association between the use of BP and the occurrence of ONJ, although we were unable to identify any definite risk factors with a retrospective study. The most frequently ONJ-associated clinical characteristics were chemotherapy treatment, steroid treatment, advanced age, female sex, anemia, parodonthopaties/dental procedures and thalidomide (in the case of MM patients).

Published
2007
Full Text
View/download PDF

44. Expression of CD10 by B-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitro.

Author

Morabito F, Mangiola M, Rapezzi D, Zupo S, Oliva BM, Ferraris AM, Spriano M, Rossi E, Stelitano C, Callea V, Cutrona G, and Ferrarini M

Subjects
ADP-ribosyl Cyclase immunology, ADP-ribosyl Cyclase metabolism, ADP-ribosyl Cyclase 1, Amino Acid Chloromethyl Ketones pharmacology, Antibodies pharmacology, Antibodies, Monoclonal pharmacology, Antigens, CD immunology, Antigens, CD metabolism, Apoptosis drug effects, Apoptosis genetics, Apoptosis immunology, B-Lymphocytes chemistry, B-Lymphocytes metabolism, Cell Line, Tumor, Etoposide pharmacology, Gene Expression Regulation, Neoplastic drug effects, Gene Expression Regulation, Neoplastic immunology, Humans, Immunoglobulin A pharmacology, Immunoglobulin D pharmacology, Immunoglobulin M pharmacology, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Membrane Glycoproteins, Palatine Tonsil, Vidarabine pharmacology, Apoptosis physiology, Leukemia, Lymphocytic, Chronic, B-Cell metabolism, Neprilysin biosynthesis, Vidarabine analogs & derivatives
Abstract

Background and Objectives: B-cell chronic lymphocytic leukemia (B-CLL) is an accumulating disease of slowly proliferating cells. CD10 is not normally expressed on the surface of B-CLL cells. The aim of this study was to ascertain whether B-CLL cells, induced into apoptosis, expressed surface CD10, since a correlation between apoptosis and CD10 expression has been demonstrated., Design and Methods: Peripheral blood cells from 31 untreated B-CLL patients were induced into apoptosis by etoposide, fludarabine or Ga(mu)-Ab treatment and tested for CD10 expression by flow cytometry. Normal CD5+ B cells were also induced into apoptosis and tested for CD10 expression., Results: CD10 positive cells were absent in B-CLL cell suspensions, but were detected following in vitro culture, and their appearance paralleled that of apoptotic cells. Treatment with etoposide, fludarabine or Ga(mu)-Ab enhanced both apoptosis and CD10 expression. Inhibition of apoptosis by VAD-fmk or Ga(delta)-Ab prevented CD10 expression. Cell separation tests following induction of apoptosis demonstrated that CD10+ cells were apoptotic. CD10+ cells were observed in the peripheral blood of two patients within a few hours following fludarabine infusion. In another patient, who failed to respond, no CD10+ cells were seen. Expression of CD10 was observed also in normal CD5+ B cells when these were induced into apoptosis., Interpretation and Conclusions: This study demonstrates that B-CLL cells, as well as normal CD5+ B cells, become CD10+ following apoptosis induction in vitro. Some of the data obtained also suggest a use for CD10 to monitor apoptosis of B-CLL in a clinical setting.

Published
2003

45. Chromosome aberrations evaluated by comparative genomic hybridization in B-cell chronic lymphocytic leukemia: correlation with CD38 expression.

Author

Ottaggio L, Viaggi S, Zunino A, Zupo S, Rossi E, Spriano M, Abbondandolo A, and Ferrarini M

Subjects
ADP-ribosyl Cyclase 1, Adult, Aged, Chromosomes, Human ultrastructure, Cytogenetic Analysis, Female, Humans, Immunophenotyping, Leukemia, Lymphocytic, Chronic, B-Cell classification, Male, Membrane Glycoproteins, Middle Aged, Nucleic Acid Hybridization, Prognosis, ADP-ribosyl Cyclase metabolism, Antigens, CD metabolism, Chromosome Aberrations, Leukemia, Lymphocytic, Chronic, B-Cell diagnosis
Abstract

Background and Objectives: B-cell chronic lymphocytic leukemia (B-CLL) results from the accumulation of monoclonal CD5+ B cells. Despite its homogeneity at cellular level, B-CLL is clinically heterogeneous. Clinical studies indicate that CD38+ B-CLL are characterized by a more aggressive clinical course than are CD38- B-CLL. On the basis of these studies and considering the established correlation between specific chromosome aberrations and the clinical course of B-CLL, it is possible that CD38+ B-CLL cases are also characterized by specific subsets of chromosomal alterations., Design and Methods: Comparative genomic hybridization (CGH) was performed on purified B-cells from peripheral blood of 52 patients with B-CLL in order to detect chromosome imbalance. The immunophenotype of the patients, including CD38 expression, was also determined by flow cytometry. The results of CGH experiments were then compared with CD38 expression., Results: We found a clear correlation between the presence of chromosomal imbalances and CD38 expression: 13/16 CD38+ cases had chromosome imbalances, most of them (12/13) correlated with a poor prognosis. Among the CD38- B-CLL patients, only 8/36 displayed chromosome imbalances; the only three cases with loss in 13q as a single aberration, considered a good prognostic marker, were in this group. Moreover, we found that cytogenetic alterations were also more complex in the CD38+ B-CLL subset, since 9/10 with two or more aberrations were in the CD38+ group., Interpretation and Conclusions: Collectively, the data reinforce the value of CD38 as a prognostic factor and indicate that genotypic/phenotypic features distinguish B-CLL subsets.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results